ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Lumos Pharma, Inc. ?
1
Positive results in Sep 24
- NET SALES(HY) At USD 1.21 MM has Grown at 127.34%
- RAW MATERIAL COST(Y) Fallen by -93.46% (YoY)
- DEBT-EQUITY RATIO (HY) Lowest at -149.51 %
2
Risky - Not traded in last 10 days
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 0%, its profits have fallen by -6.4%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Lumos Pharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals: Major should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals: Major)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Lumos Pharma, Inc. for you?
Low Risk, High Return
Absolute
Risk Adjusted
Volatility
Lumos Pharma, Inc.
48.63%
inf
nan%
S&P 500
13.22%
0.61
20.23%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.11%
EBIT Growth (5y)
4.28%
EBIT to Interest (avg)
-31.96
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.50
Sales to Capital Employed (avg)
0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
32.81%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.64
EV to EBIT
-0.83
EV to EBITDA
-0.83
EV to Capital Employed
-12.18
EV to Sales
13.67
PEG Ratio
NA
Dividend Yield
8985.11%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-710.54%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Lumos Pharma, Inc.
Net Sales
At USD 1.21 MM has Grown at 127.34%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD -7.64 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -7.47 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -7.47 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.9
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -149.51 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 12.75%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -93.46% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Lumos Pharma, Inc.
Operating Cash Flow
Lowest at USD -31.67 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Cash and Eqv
Lowest at USD 30.32 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
